Abstract
Total hip arthroplasty (THA) is a cornerstone intervention for advanced hip arthritis, but perioperative blood loss poses a significant clinical challenge, often leading to increased transfusion rates, prolonged hospitalization, and higher healthcare costs. Tranexamic acid (TXA), an antifibrinolytic agent, has emerged as an effective strategy for minimizing surgical bleeding. While the benefits of TXA in THA are well established, Mohabey et al. (2025) uniquely examined its comparative efficacy in inflammatory arthritis (IA) versus degenerative arthritis (DA) in an Indian population. Their retrospective cohort study suggests a differential response to TXA depending on arthritis type, with a more pronounced but statistically non-significant benefit in DA. This commentary contextualizes these findings within existing literature, explores mechanistic insights into differential TXA efficacy, highlights clinical implications, and identifies key areas for future research.
Keywords
Antifibrinolytic agent, Arthroplasty hip, Arthritis, Hemorrhage, Postoperative complications